Investigation of Hepatotoxicity of Antituberculosis Medications in some Hospitals, Khartoum State

TajEldin I M; Reem M Husein; Abd Elwahab H  M

doi:10.52981/sjms.v8i2.895

TajEldin I M Department of Pharmacology, Faculty of Pharmacy, University of Gezira, Sudan
Reem M Husein Ministry of Health, Sudan
Abd Elwahab H M Department of Pharmacology and Toxicology, Medicinal and Aromatic Plant Research Institute, National Center for Research, Sudan

DOI: https://doi.org/10.52981/sjms.v8i2.895

Keywords: Tuberculosis, Rifampicin, Isoniazid, Pyrazinamide, Hepatotoxicity;, Liver Function Tests

Abstract

Background: Tuberculosis (TB) is an ancient disease still kills more than two million people every year, despite the fact that a cure has been available for over 50 years. Some antituberculosis agents cause hepatotoxicity as a major adverse drug reaction.
Objectives: This study was designed to investigate rifampicin, isoniazid and pyrazinamide induced-hepatotoxicity among TB patients in Sudan.
Methods: Sudanese in-patients (n=57) their ages ranged between 15 to 76 years, with active pulmonary tuberculosis and normal pretreatment liver function, received rifampicin (10 mg/Kg/day), isoniazid (5 mg/Kg/day) and pyrazinamide (20 mg/Kg/day) daily for two months, were involved in this study. Liver function test was performed for each patient separately at week 8, 9 and 10, to assess direct and indirect bilirubin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, albumin and total protein levels.
Results: Liver function tests revealed that 10 (17.5%) patients had high serum total bilirubin level, whereas 46 (80.7%) of them showed significant alteration in direct (conjugated) bilirubin level. Five (8.7%) and 23 (40.3%) patients demonstrated increased serum level of alanine aminotransferase and alkaline phosphatase respectively. Moreover, 15 (26.3%) of the treated patients experienced higher serum levels of aspartate aminotransferase. Hepatotoxicity and symptoms of liver failure occurred in 9 (15.7%) patients, which necessitate treatment discontinuation. Thirty eight (66.6 %) of the treated patients developed alteration in serum albumin level, whereas slight alteration in total protein level was found in 12 (21%) of the TB patients.
Conclusions: Biochemical investigations and clinical monitoring of patients treated with antituberculosis drugs are essential to decrease hepatotoxicity of these agents.

Author Biography

Reem M Husein, Ministry of Health, Sudan

Clinical Pharmacologist in Governmental Sector

References

1. USAID Health: Infectious diseases, Tuberculosis, News/World TB Day 2005.
2. Harries A, Maher D, Graham S. (2004). TB/HIV a 7clinical manual, second edition. World Health Organization, Geneva;41-127.2.
3. World Health Organization (2003) (PDF). Treatment of Tuberculosis: for National Programms. Third Edition, WHO/CDS/TB/2003.313,Geneva
4. World Health Organization (2001). Global Tuberculosis Control. (WHO) report, 2001. Geneva, Switzerland: WHO/CDS/TB;2001.287.
5. Nyblom H, Berggren U, Balldin J, Olsson R (2004). "High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking". AlcoholAlcohol. 39 (4): 336–339
6. Paul T. Giboney(2005).Mildly Elevated Liver Transaminase Levels in the Asymptomatic Patient American Family Physician Journal 15;71(6):1105-1110
7. AbdulRaheemAlhumarani, MD, Asssim, A and Ahmed Alansari, MD (2002). Are we still encountering tuberculosis in ENT outpatient department? Journal of Arab board of Medical Specialization. V6:151-154
8. Nehaul, LK (2005). Tuberculosis. Clinical pharmacy and therapeutics. Third edition, Church, London: 583-593
9. Steele MA, Burk RF, Desprez RM (1991). Hepatitis with isoniazid and rifampicin; A meta-analysis. Chest; 99:465-471. 9. Shakya R, Rao BS, Shrestha B (2004). Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother; 38(6):1074-1079.
10. Watson D, Rogers JA (May 1961). A study of six representative methods of plasma bilirubin analysis". Journal of Clinical Pathology.14: 271-8.
11. Sanches, Arcillal;Vilchez, JM; Garcia, de la Torre, M; Fernandez, X and Noguerado, A (2004). Treatment of latent tuberculosis among homeless population. Comparison between two therapeutic approaches. Medina. Clinica. (Barc). V 122 (11): 57-59
12. Mahashur AA, Prabhudesai PP (1991). Hepatitis 7and antitubercular therapy. Journal of Association of Physicians of India; 39: 595-6.
13. Monica, Cheebrough (1999). Mycobacteria in Medical laboratory manual for tropical countries. 2nd edition V 11: 289-297.
14. World Health Organization (2003). Treatment of tuberculosis: Guidelines for National Programmes. Third Edition WHO/CDS/TB/2003.313, Geneva.
15. Durand F, Bernuau J, Pessayre D, Samuel D, Deggott, Bismuth H, et al (1995). Deliterous influence of PZA on the outcome of patient with fulminant or subfulminant liver failure during antiTB treatment including INH. Hepatology;21:929- 32.
16. Shakya R, Rao BS, Shrestha B (2004). Evaluation of risk factors for atni tuberculosis drug induced hepatotoxicity in Nep- alese population. Ann Pharmacother; 38(6):1074-9
17. Ungo JR, Jones D, Askin D (1998). Anti-TB drugs-related hepatotoxicity; the role of hepatitis C &the human immuno-deficiency virus. Am J RespirCrit Care Med;157:1871-6
18. Singh J, Garg PK. Thakur VS, Tandon RK (1995). Anti-TB treatment induced hepatotoxicity: Does acetylator status matters. Indian J Physiol Pharmacol;39(1):43-6.
19. Mehta S (1990). Malnutrition and drugs: Clinical implications. DevPharmacol Ther;15(3-4):159-65.
20. Mitchell JR, Jimmerman HJ, Ishak KG, Timbrell JA, Snodgrass WR, Nelson SD (1978). INHinduced liver injury; Clinical spectrum, pathology, and possible pathogenesis. Ann Intern Med;84:181-92